Last 12 months
Inside the activity.
0 purchase rows · 240 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 200 |
| Dec 2025 | 0 | 3 |
| Jan 2026 | 0 | 31 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 2 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 3 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 10, 2025 Filed Feb 12, 2025 21:16 UTC |
Hakim AnatEVP, GC & Secretary
|
GrantRestricted Stock Unit · Derivative | 6,700 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-25-000041 · wk-form4_1739395004.xml · derivative · entry 3 Hakim Anat · CIK 0001685556 · EVP, GC & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,700 Underlying: Common Stock · 6,700 shares Expires 2026-02-01 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 21:16 UTC |
Hakim AnatEVP, GC & Secretary
|
GrantCommon Stock | 10,320.956 | $868.88 | $8,967,672.25 |
DisclosureSEC source: 0000059478-25-000041 · wk-form4_1739395004.xml · nonDerivative · entry 1 Hakim Anat · CIK 0001685556 · EVP, GC & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,837.5 Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 21:19 UTC |
Ricks David ADirector · President, Chair, and CEO
|
GrantRestricted Stock Unit · Derivative | 31,932 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-25-000043 · wk-form4_1739395137.xml · derivative · entry 6 Ricks David A · CIK 0001538604 · Director · President, Chair, and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,932 Underlying: Common Stock · 31,932 shares Expires 2026-02-01 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 21:19 UTC |
Ricks David ADirector · President, Chair, and CEO
|
GrantCommon Stock | 55,131.56 | $868.88 | $47,902,709.85 |
DisclosureSEC source: 0000059478-25-000043 · wk-form4_1739395137.xml · nonDerivative · entry 1 Ricks David A · CIK 0001538604 · Director · President, Chair, and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 539,613.167 Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 21:20 UTC |
Dozier EricEVP, HR & Diversity
|
GrantRestricted Stock Unit · Derivative | 2,858 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-25-000045 · wk-form4_1739395216.xml · derivative · entry 3 Dozier Eric · CIK 0001955972 · EVP, HR & Diversity 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,858 Underlying: Common Stock · 2,858 shares Expires 2026-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 21:20 UTC |
Dozier EricEVP, HR & Diversity
|
GrantCommon Stock | 919.525 | $868.88 | $798,956.88 |
DisclosureSEC source: 0000059478-25-000045 · wk-form4_1739395216.xml · nonDerivative · entry 1 Dozier Eric · CIK 0001955972 · EVP, HR & Diversity 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,962.122 Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 21:21 UTC |
Zakrowski Donald ASVP, Finance, & CAO
|
GrantRestricted Stock Unit · Derivative | 216.389 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-25-000047 · wk-form4_1739395274.xml · derivative · entry 3 Zakrowski Donald A · CIK 0001561539 · SVP, Finance, & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 216.389 Underlying: Common Stock · 216.389 shares Expires 2028-02-16 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 21:21 UTC |
Zakrowski Donald ASVP, Finance, & CAO
|
GrantCommon Stock | 1,359.659 | $868.88 | $1,181,380.51 |
DisclosureSEC source: 0000059478-25-000047 · wk-form4_1739395274.xml · nonDerivative · entry 1 Zakrowski Donald A · CIK 0001561539 · SVP, Finance, & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,839.659 Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 21:22 UTC |
Hernandez EdgardoEVP & Pres., Mfg. Operations
|
GrantRestricted Stock Unit · Derivative | 3,572 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-25-000049 · wk-form4_1739395357.xml · derivative · entry 3 Hernandez Edgardo · CIK 0001861052 · EVP & Pres., Mfg. Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,572 Underlying: Common Stock · 3,572 shares Expires 2026-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 21:22 UTC |
Hernandez EdgardoEVP & Pres., Mfg. Operations
|
GrantCommon Stock | 5,974.141 | $868.88 | $5,190,811.63 |
DisclosureSEC source: 0000059478-25-000049 · wk-form4_1739395357.xml · nonDerivative · entry 1 Hernandez Edgardo · CIK 0001861052 · EVP & Pres., Mfg. Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,171.76 Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 21:24 UTC |
Jonsson PatrikEVP&Pres, CardMetHlth, LLY USA
|
GrantRestricted Stock Unit · Derivative | 3,930 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-25-000051 · wk-form4_1739395443.xml · derivative · entry 3 Jonsson Patrik · CIK 0001786054 · EVP&Pres, CardMetHlth, LLY USA 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,930 Underlying: Common Stock · 3,930 shares Expires 2026-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 21:24 UTC |
Jonsson PatrikEVP&Pres, CardMetHlth, LLY USA
|
GrantCommon Stock | 7,170.498 | $868.88 | $6,230,302.30 |
DisclosureSEC source: 0000059478-25-000051 · wk-form4_1739395443.xml · nonDerivative · entry 1 Jonsson Patrik · CIK 0001786054 · EVP&Pres, CardMetHlth, LLY USA 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,650.639 Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 21:26 UTC |
Montarce LucasEVP & CFO
|
GrantCommon Stock | 2,895.932 | $868.88 | $2,516,217.40 |
DisclosureSEC source: 0000059478-25-000053 · wk-form4_1739395561.xml · nonDerivative · entry 1 Montarce Lucas · CIK 0001752447 · EVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,969.736 Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 21:27 UTC |
Rau DiogoEVP & CIDO
|
GrantRestricted Stock Unit · Derivative | 3,752 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-25-000055 · wk-form4_1739395622.xml · derivative · entry 2 Rau Diogo · CIK 0001860253 · EVP & CIDO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,752 Underlying: Common Stock · 3,752 shares Expires 2026-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 21:27 UTC |
Rau DiogoEVP & CIDO
|
GrantCommon Stock | 6,815.202 | $868.88 | $5,921,592.71 |
DisclosureSEC source: 0000059478-25-000055 · wk-form4_1739395622.xml · nonDerivative · entry 1 Rau Diogo · CIK 0001860253 · EVP & CIDO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,718.908 Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 21:28 UTC |
Van Naarden JacobEVP & Pres., Lilly Oncology
|
GrantRestricted Stock Unit · Derivative | 4,108 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-25-000057 · wk-form4_1739395681.xml · derivative · entry 4 Van Naarden Jacob · CIK 0001661254 · EVP & Pres., Lilly Oncology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,108 Underlying: Common Stock · 4,108 shares Expires 2026-02-01 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 21:28 UTC |
Van Naarden JacobEVP & Pres., Lilly Oncology
|
GrantCommon Stock | 6,103.824 | $868.88 | $5,303,490.60 |
DisclosureSEC source: 0000059478-25-000057 · wk-form4_1739395681.xml · nonDerivative · entry 1 Van Naarden Jacob · CIK 0001661254 · EVP & Pres., Lilly Oncology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,561.985 Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 21:29 UTC |
White Anne E.EVP & Pres, Lilly Neuroscience
|
GrantRestricted Stock Unit · Derivative | 3,572 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-25-000059 · wk-form4_1739395756.xml · derivative · entry 2 White Anne E. · CIK 0001752313 · EVP & Pres, Lilly Neuroscience 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,572 Underlying: Common Stock · 3,572 shares Expires 2026-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 21:29 UTC |
White Anne E.EVP & Pres, Lilly Neuroscience
|
GrantCommon Stock | 6,828.871 | $868.88 | $5,933,469.43 |
DisclosureSEC source: 0000059478-25-000059 · wk-form4_1739395756.xml · nonDerivative · entry 1 White Anne E. · CIK 0001752313 · EVP & Pres, Lilly Neuroscience 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,209.769 Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 21:30 UTC |
Yuffa IlyaEVP & President, LLY Int'l
|
GrantRestricted Stock Unit · Derivative | 3,394 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-25-000061 · wk-form4_1739395815.xml · derivative · entry 2 Yuffa Ilya · CIK 0001826001 · EVP & President, LLY Int'l 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,394 Underlying: Common Stock · 3,394 shares Expires 2026-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 21:30 UTC |
Yuffa IlyaEVP & President, LLY Int'l
|
GrantCommon Stock | 7,123.348 | $868.88 | $6,189,334.61 |
DisclosureSEC source: 0000059478-25-000061 · wk-form4_1739395815.xml · nonDerivative · entry 1 Yuffa Ilya · CIK 0001826001 · EVP & President, LLY Int'l 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,759.971 Read SEC document |
| February 06, 2025 Filed Feb 7, 2025 21:00 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 274 | $887.32 | $243,124.58 |
DisclosureSEC source: 0001415889-25-003338 · form4-02072025_040211.xml · nonDerivative · entry 22 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,681,978 F22 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $887.25 to $887.34, inclusive. Read SEC document |
| February 06, 2025 Filed Feb 7, 2025 21:00 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 2,325 | $886.66 | $2,061,491.48 |
DisclosureSEC source: 0001415889-25-003338 · form4-02072025_040211.xml · nonDerivative · entry 21 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,682,252 F21 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $886.20 to $887.18, inclusive. Read SEC document |
| February 06, 2025 Filed Feb 7, 2025 21:00 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 2,700 | $885.71 | $2,391,422.40 |
DisclosureSEC source: 0001415889-25-003338 · form4-02072025_040211.xml · nonDerivative · entry 20 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,684,577 F20 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $885.175 to $886.15, inclusive. Read SEC document |
| February 06, 2025 Filed Feb 7, 2025 21:00 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 3,205 | $884.56 | $2,835,024.42 |
DisclosureSEC source: 0001415889-25-003338 · form4-02072025_040211.xml · nonDerivative · entry 19 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,687,277 F19 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $884.095 to $885.00, inclusive. Read SEC document |
| February 06, 2025 Filed Feb 7, 2025 21:00 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 4,855 | $883.54 | $4,289,591.56 |
DisclosureSEC source: 0001415889-25-003338 · form4-02072025_040211.xml · nonDerivative · entry 18 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,690,482 F18 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $883.075 to $883.99, inclusive. Read SEC document |
| February 06, 2025 Filed Feb 7, 2025 21:00 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 2,239 | $882.44 | $1,975,780.92 |
DisclosureSEC source: 0001415889-25-003338 · form4-02072025_040211.xml · nonDerivative · entry 17 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,695,337 F17 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $882.04 to $882.96, inclusive. Read SEC document |
| February 06, 2025 Filed Feb 7, 2025 21:00 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 4,151 | $881.37 | $3,658,562.72 |
DisclosureSEC source: 0001415889-25-003338 · form4-02072025_040211.xml · nonDerivative · entry 16 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,697,576 F16 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $881.00 to $881.73, inclusive. Read SEC document |
| February 06, 2025 Filed Feb 7, 2025 21:00 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 12,726 | $880.46 | $11,204,670.33 |
DisclosureSEC source: 0001415889-25-003338 · form4-02072025_040211.xml · nonDerivative · entry 15 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,701,727 F15 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $880.00 to $880.96, inclusive. Read SEC document |
| February 06, 2025 Filed Feb 7, 2025 21:00 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 12,408 | $879.54 | $10,913,381.95 |
DisclosureSEC source: 0001415889-25-003338 · form4-02072025_040211.xml · nonDerivative · entry 14 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,714,453 F14 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $878.945 to $879.94, inclusive. Read SEC document |
| February 06, 2025 Filed Feb 7, 2025 21:00 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 6,228 | $878.36 | $5,470,438.54 |
DisclosureSEC source: 0001415889-25-003338 · form4-02072025_040211.xml · nonDerivative · entry 13 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,726,861 F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $877.93 to $878.925, inclusive. Read SEC document |
| February 06, 2025 Filed Feb 7, 2025 21:00 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 9,278 | $877.48 | $8,141,213.05 |
DisclosureSEC source: 0001415889-25-003338 · form4-02072025_040211.xml · nonDerivative · entry 12 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,733,089 F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $876.93 to $877.84, inclusive. Read SEC document |
| February 06, 2025 Filed Feb 7, 2025 21:00 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 8,900 | $876.49 | $7,800,769.90 |
DisclosureSEC source: 0001415889-25-003338 · form4-02072025_040211.xml · nonDerivative · entry 11 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,742,367 F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $875.93 to $876.925, inclusive. Read SEC document |
| February 06, 2025 Filed Feb 7, 2025 21:00 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 9,301 | $875.21 | $8,140,291.01 |
DisclosureSEC source: 0001415889-25-003338 · form4-02072025_040211.xml · nonDerivative · entry 10 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,751,267 F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $874.925 to $875.87, inclusive. Read SEC document |
| February 06, 2025 Filed Feb 7, 2025 21:00 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 15,032 | $874.35 | $13,143,199.14 |
DisclosureSEC source: 0001415889-25-003338 · form4-02072025_040211.xml · nonDerivative · entry 9 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,760,568 F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $873.92 to $874.835, inclusive. Read SEC document |
| February 06, 2025 Filed Feb 7, 2025 21:00 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 15,637 | $873.42 | $13,657,715.45 |
DisclosureSEC source: 0001415889-25-003338 · form4-02072025_040211.xml · nonDerivative · entry 8 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,775,600 F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $872.91 to $873.895, inclusive. Read SEC document |
| February 06, 2025 Filed Feb 7, 2025 21:00 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 12,156 | $872.24 | $10,602,937.28 |
DisclosureSEC source: 0001415889-25-003338 · form4-02072025_040211.xml · nonDerivative · entry 7 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,791,237 F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $871.85 to $872.84, inclusive. Read SEC document |
| February 06, 2025 Filed Feb 7, 2025 21:00 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 18,918 | $871.32 | $16,483,688.51 |
DisclosureSEC source: 0001415889-25-003338 · form4-02072025_040211.xml · nonDerivative · entry 6 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,803,393 F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $870.845 to $871.84, inclusive. Read SEC document |
| February 06, 2025 Filed Feb 7, 2025 21:00 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 28,727 | $870.39 | $25,003,578.62 |
DisclosureSEC source: 0001415889-25-003338 · form4-02072025_040211.xml · nonDerivative · entry 5 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,822,311 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $869.84 to $870.83, inclusive. Read SEC document |
| February 06, 2025 Filed Feb 7, 2025 21:00 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 23,371 | $869.23 | $20,314,657.48 |
DisclosureSEC source: 0001415889-25-003338 · form4-02072025_040211.xml · nonDerivative · entry 4 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,851,038 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $868.82 to $869.76, inclusive. Read SEC document |
| February 06, 2025 Filed Feb 7, 2025 21:00 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 5,736 | $868.20 | $4,979,983.73 |
DisclosureSEC source: 0001415889-25-003338 · form4-02072025_040211.xml · nonDerivative · entry 3 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,874,409 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $867.74 to $868.645, inclusive. Read SEC document |
| February 06, 2025 Filed Feb 7, 2025 21:00 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 6,763 | $867.19 | $5,864,778.92 |
DisclosureSEC source: 0001415889-25-003338 · form4-02072025_040211.xml · nonDerivative · entry 2 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,880,145 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $866.72 to $867.67, inclusive. Read SEC document |
| February 06, 2025 Filed Feb 7, 2025 21:00 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 5,070 | $866.07 | $4,390,959.69 |
DisclosureSEC source: 0001415889-25-003338 · form4-02072025_040211.xml · nonDerivative · entry 1 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,886,908 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $865.605 to $866.50, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1), (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13), (14), (15), (16), (17), (18), (19), (20), (21), and (22) to this Form 4. Read SEC document |
| February 01, 2025 Filed Feb 4, 2025 21:19 UTC |
Hakim AnatEVP, GC & Secretary
|
Exercise / conversionRestricted Stock Unit · Derivative | 4,904 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-25-000018 · wk-form4_1738703991.xml · derivative · entry 4 Hakim Anat · CIK 0001685556 · EVP, GC & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,904 shares Expires 2025-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2025 Filed Feb 4, 2025 21:19 UTC |
Hakim AnatEVP, GC & Secretary
|
Tax withholdingCommon Stock | 2,166.456 | $811.08 | $1,757,169.13 |
DisclosureSEC source: 0000059478-25-000018 · wk-form4_1738703991.xml · nonDerivative · entry 2 Hakim Anat · CIK 0001685556 · EVP, GC & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,516.544 Read SEC document |
| February 01, 2025 Filed Feb 4, 2025 21:19 UTC |
Hakim AnatEVP, GC & Secretary
|
Exercise / conversionCommon Stock | 4,904 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-25-000018 · wk-form4_1738703991.xml · nonDerivative · entry 1 Hakim Anat · CIK 0001685556 · EVP, GC & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,683 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2025 Filed Feb 4, 2025 21:21 UTC |
Hernandez EdgardoEVP & Pres., Mfg. Operations
|
Exercise / conversionRestricted Stock Unit · Derivative | 2,861 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-25-000020 · wk-form4_1738704064.xml · derivative · entry 4 Hernandez Edgardo · CIK 0001861052 · EVP & Pres., Mfg. Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,861 shares Expires 2025-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2025 Filed Feb 4, 2025 21:21 UTC |
Hernandez EdgardoEVP & Pres., Mfg. Operations
|
Tax withholdingCommon Stock | 1,281.582 | $811.08 | $1,039,465.53 |
DisclosureSEC source: 0000059478-25-000020 · wk-form4_1738704064.xml · nonDerivative · entry 2 Hernandez Edgardo · CIK 0001861052 · EVP & Pres., Mfg. Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,197.619 Read SEC document |
| February 01, 2025 Filed Feb 4, 2025 21:21 UTC |
Hernandez EdgardoEVP & Pres., Mfg. Operations
|
Exercise / conversionCommon Stock | 2,861 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-25-000020 · wk-form4_1738704064.xml · nonDerivative · entry 1 Hernandez Edgardo · CIK 0001861052 · EVP & Pres., Mfg. Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,479.201 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2025 Filed Feb 4, 2025 21:23 UTC |
Jonsson PatrikEVP&Pres, CardMetHlth, LLY USA
|
Exercise / conversionRestricted Stock Unit · Derivative | 3,433 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-25-000022 · wk-form4_1738704180.xml · derivative · entry 4 Jonsson Patrik · CIK 0001786054 · EVP&Pres, CardMetHlth, LLY USA 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,433 shares Expires 2025-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.